Lazard Asset Management’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.61M | Sell |
13,539
-857
| -6% | -$550K | 0.01% | 466 |
|
|
2025
Q4 | $9.74M | Sell |
14,396
-1,151
| -7% | -$784K | 0.02% | 415 |
|
|
2025
Q3 | $9.93M | Buy |
15,547
+5,840
| +60% | +$3.54M | 0.01% | 426 |
|
|
2025
Q2 | $5.21M | Buy |
9,707
+722
| +8% | +$345K | 0.01% | 722 |
|
|
2025
Q1 | $3.77M | Buy |
8,985
+1,208
| +16% | +$525K | 0.01% | 765 |
|
|
2024
Q4 | $3.21M | Buy |
7,777
+338
| +5% | +$148K | ﹤0.01% | 742 |
|
|
2024
Q3 | $3.76M | Sell |
7,439
-25,715
| -78% | -$12.5M | 0.01% | 711 |
|
|
2024
Q2 | $16.2M | Sell |
33,154
-4,488
| -12% | -$2.25M | 0.02% | 423 |
|
|
2024
Q1 | $20.3M | Buy |
37,642
+30,804
| +450% | +$16.8M | 0.02% | 382 |
|
|
2023
Q4 | $3.79M | Sell |
6,838
-1,184
| -15% | -$556K | ﹤0.01% | 733 |
|
|
2023
Q3 | $3.51M | Sell |
8,022
-9,485
| -54% | -$4.73M | ﹤0.01% | 766 |
|
|
2023
Q2 | $8.79M | Buy |
17,507
+7,038
| +67% | +$3.37M | 0.01% | 585 |
|
|
2023
Q1 | $5.24M | Buy |
10,469
+1,471
| +16% | +$704K | 0.01% | 720 |
|
|
2022
Q4 | $3.67M | Sell |
8,998
-2,614
| -23% | -$1.01M | 0.01% | 785 |
|
|
2022
Q3 | $3.78M | Sell |
11,612
-3,977
| -26% | -$1.46M | 0.01% | 764 |
|
|
2022
Q2 | $5.47M | Sell |
15,589
-48,858
| -76% | -$19.9M | 0.01% | 724 |
|
|
2022
Q1 | $35.3M | Sell |
64,447
-77,263
| -55% | -$40.6M | 0.04% | 343 |
|
|
2021
Q4 | $93.3M | Sell |
141,710
-19,526
| -12% | -$12.3M | 0.1% | 184 |
|
|
2021
Q3 | $100M | Buy |
161,236
+45,865
| +40% | +$30.8M | 0.11% | 173 |
|
|
2021
Q2 | $72.9M | Buy |
115,371
+4,747
| +4% | +$2.62M | 0.08% | 213 |
|
|
2021
Q1 | $54.1M | Buy |
110,624
+26,615
| +32% | +$13.3M | 0.07% | 232 |
|
|
2020
Q4 | $42M | Sell |
84,009
-64,969
| -44% | -$29.1M | 0.05% | 286 |
|
|
2020
Q3 | $58.6M | Buy |
148,978
+110,560
| +288% | +$40.9M | 0.08% | 191 |
|
|
2020
Q2 | $12.7M | Sell |
38,418
-625
| -2% | -$181K | 0.02% | 438 |
|
|
2020
Q1 | $9.46M | Buy |
39,043
+5,711
| +17% | +$1.49M | 0.02% | 439 |
|
|
2019
Q4 | $8.7M | Sell |
33,332
-6,076
| -15% | -$1.6M | 0.01% | 476 |
|
|
2019
Q3 | $10.7M | Sell |
39,408
-10,212
| -21% | -$2.84M | 0.02% | 438 |
|
|
2019
Q2 | $13.7M | Sell |
49,620
-2,596
| -5% | -$640K | 0.02% | 397 |
|
|
2019
Q1 | $11.7M | Buy |
52,216
+48,350
| +1,251% | +$9.98M | 0.02% | 404 |
|
|
2018
Q4 | $719K | Sell |
3,866
-70,022
| -95% | -$14.4M | ﹤0.01% | 767 |
|
|
2018
Q3 | $18.4M | Buy |
73,888
+13,042
| +21% | +$3.17M | 0.03% | 327 |
|
|
2018
Q2 | $13.3M | Sell |
60,846
-38,806
| -39% | -$8M | 0.02% | 372 |
|
|
2018
Q1 | $19.1M | Buy |
99,652
+98,039
| +6,078% | +$18.1M | 0.03% | 311 |
|
|
2017
Q4 | $252K | Sell |
1,613
-120,728
| -99% | -$19M | ﹤0.01% | 856 |
|
|
2017
Q3 | $19M | Sell |
122,341
-4,389
| -3% | -$694K | 0.03% | 297 |
|
|
2017
Q2 | $20.5M | Buy |
126,730
+38,608
| +44% | +$6.27M | 0.04% | 290 |
|
|
2017
Q1 | $13.6M | Sell |
88,122
-17,169
| -16% | -$2.37M | 0.03% | 387 |
|
|
2016
Q4 | $12.3M | Buy |
105,291
+7,720
| +8% | +$881K | 0.03% | 390 |
|
|
2016
Q3 | $11M | Buy |
97,571
+48,291
| +98% | +$5.09M | 0.02% | 397 |
|
|
2016
Q2 | $4.58M | Buy |
+49,280
| New | +$4.23M | 0.01% | 517 |
|
|
2015
Q1 | – | Sell |
-34,488
| Closed | -$2.56M | – | 1165 |
|
|
2014
Q4 | $2.56M | Buy |
+34,488
| New | +$2.42M | 0.01% | 633 |
|
Other funds holding IDXX
VCM
VPM
Lazard Asset Management's IDXX Position: Q1 2026 in Review
Lazard Asset Management reduced its Idexx Laboratories (IDXX) stake by 6% in Q1 2026, selling an estimated $550K and leaving 13,539 shares worth $7.61M. The position accounts for 0.01% of the portfolio, ranked #466.
Lazard Asset Management first reported a position in IDXX in Q4 2014 and has held it in 41 quarters since. The position peaked at $100M in Q3 2021. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- Lazard Asset Management held 13,539 shares of Idexx Laboratories worth $7.61M as of Q1 2026.
- Lazard Asset Management sold 857 Idexx Laboratories shares in Q1 2026, an estimated $550K.
- Idexx Laboratories made up 0.01% of Lazard Asset Management's portfolio in Q1 2026, its #466 holding.
- Lazard Asset Management first reported a position in Idexx Laboratories in Q4 2014 and has held it in 41 quarters since.
- Lazard Asset Management's Idexx Laboratories position peaked at $100M in Q3 2021.
- 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.